Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31613816 | 0.88 | CDC25B (0.64) | CDC25BPTPN1KDM4EALDH1A1HPGD | |
| SCHEMBL2510203 | 0.88 | CDC25B (0.64) | CDC25BPTPN1KDM4EALDH1A1HPGD | |
| SCHEMBL14052345 | 0.86 | PARP1 (0.50) | CDC25BHPGDPARP1LMNACNR1 | |
| SCHEMBL14052469 | 0.82 | HPGD (0.64) | KDM4EALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL3013825 | 0.78 | HSD17B1 (0.67) | SMN1; SMN2NPC1RAB9AHDAC4HDAC2 | |
| SCHEMBL3327762 | 0.78 | MTNR1A (0.70) | CDC25BKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13241099 | 0.76 | CYP1A2 (0.52) | KDM4EALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL1162404 | 0.76 | CDC25B (0.80) | CDC25BKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2099558 | 0.76 | PTPN1 (0.57) | CDC25BPTPN1KDM4EALDH1A1HPGD | |
| SCHEMBL13828205 | 0.76 | KDM4E (0.58) | KDM4EALDH1A1HPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1279902-C | Apoptosis-inducing adamantyl derivatives and their use in the preparation of anti-cancer drugs | GALDERMA RECH S DERMATOLOGIQUE (FR) | 2006-10-18 | — | — | CN | disclosed |
| EP-1272176-A4 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-29 | — | — | EP | disclosed |
| EP-0920312-B1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-08 | — | — | EP | disclosed |
| US-6825226-B2 | ANTICANCER AGENTS; UROGENITAL DISORDERS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-04-17 | — | — | US | disclosed |
| EP-1272176-A1 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | Galderma Research & Development, S.N.C. (FR) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001056563-A9 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2002-10-31 | — | — | WO | disclosed |
| US-6462064-B1 | SUCH AS 6-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-2-NAPHTHOIC ACID, 2-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-5-BENZIMIDAZOLE CARBOXY-LIC ACID, AND 6-(3-(1-ADAMANTYL)-4,5-METHYLENEDIOXYPHENYL)-2-NAPHTHOIC ACID | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-10-08 | — | — | US | disclosed |
| WO-2001056563-A1 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-08-09 | — | — | WO | disclosed |
| EP-0920312-A4 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2000-11-02 | — | — | EP | disclosed |
| US-6127415-A | ADAMANTYL DERIVATIVE CONTAINING-RETINOID RELATED COMPOUNDS AS ANTICARCINOGENIC AGENTS; SKIN DISORDERS;COSMETICS; AGING RESISTANCE; ALOPEIA | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-10-03 | — | — | US | disclosed |
| CN-1230111-A | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents | GALDERMA RES & DEV (FR) | 1999-09-29 | — | — | CN | disclosed |
| EP-0920312-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | Galderma Research & Development (FR) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998001132-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | CASP3, BAD, RARA | CDC25B 121/4885PTPN1 2845/4885KDM4E 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.